Kaveri Pohlman
Stock Analyst at Clear Street
(2.14)
# 4,006
Out of 5,182 analysts
34
Total ratings
40.62%
Success rate
-0.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | $104 → $116 | $100.32 | +15.63% | 1 | Apr 7, 2026 | |
| EVMN Evommune | Initiates: Buy | $53 | $25.96 | +104.16% | 1 | Mar 18, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $45 → $70 | $16.65 | +320.42% | 1 | Mar 11, 2026 | |
| ERAS Erasca | Maintains: Buy | $11 → $20 | $21.76 | -8.09% | 1 | Mar 6, 2026 | |
| JANX Janux Therapeutics | Downgrades: Hold | $32 → $12 | $15.03 | -20.16% | 3 | Jan 20, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $12 | $2.08 | +476.92% | 1 | Dec 30, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $61 → $99 | $45.77 | +116.30% | 1 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $200 | $121.77 | +64.24% | 1 | Dec 5, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $25 | $24.42 | +2.38% | 1 | Nov 25, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $14.25 | +47.37% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.27 | +241.56% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $5.79 | +400.86% | 1 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 | $67.19 | -31.53% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $31.25 | +2.40% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.14 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $47 | $26.94 | +74.46% | 3 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $30 | $12.91 | +132.38% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $12.65 | +200.40% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $4.81 | +4.06% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.91 | +318.85% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $45.27 | -40.36% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $25.00 | +180.00% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $7.54 | +59.26% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $4.37 | +83.28% | 2 | Jul 7, 2022 |
Protagonist Therapeutics
Apr 7, 2026
Maintains: Buy
Price Target: $104 → $116
Current: $100.32
Upside: +15.63%
Evommune
Mar 18, 2026
Initiates: Buy
Price Target: $53
Current: $25.96
Upside: +104.16%
MoonLake Immunotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $45 → $70
Current: $16.65
Upside: +320.42%
Erasca
Mar 6, 2026
Maintains: Buy
Price Target: $11 → $20
Current: $21.76
Upside: -8.09%
Janux Therapeutics
Jan 20, 2026
Downgrades: Hold
Price Target: $32 → $12
Current: $15.03
Upside: -20.16%
Palisade Bio
Dec 30, 2025
Initiates: Buy
Price Target: $12
Current: $2.08
Upside: +476.92%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $61 → $99
Current: $45.77
Upside: +116.30%
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $200
Current: $121.77
Upside: +64.24%
Jade Biosciences
Nov 25, 2025
Initiates: Buy
Price Target: $25
Current: $24.42
Upside: +2.38%
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $14.25
Upside: +47.37%
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $5.27
Upside: +241.56%
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $5.79
Upside: +400.86%
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $67.19
Upside: -31.53%
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $31.25
Upside: +2.40%
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.14
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $26.94
Upside: +74.46%
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $12.91
Upside: +132.38%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $12.65
Upside: +200.40%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $4.81
Upside: +4.06%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.91
Upside: +318.85%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $45.27
Upside: -40.36%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $25.00
Upside: +180.00%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $7.54
Upside: +59.26%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $4.37
Upside: +83.28%